Aster DM Quality Care Ltd Q4 FY2023 Concall Summary

Key Takeaways

• Restructuring is the quarter's centerpiece: Binding bids for the GCC business are expected in Q1 FY24, with a close targeted before end-Q2; management frames the separation as a major value-unlock catalyst.
• India delivered strong growth, GCC absorbed investment pain: India revenue rose 32% YoY in Q4 with EBITDA up 62%, while GCC EBITDA was flat as three new hospitals, 24 pharmacies and six clinics opened in a single year.
• New hospital drag is quantified and temporary: Five hospitals opened in one year, with an aim to break even within 18 to 24 months of opening; Aster Narayanadri already broke even in its first quarter.
• Margins are a tale of two businesses: India Hospitals & Clinics EBITDA margin reached 15.8% in Q4, while GCC mature hospitals operate at 17% with a clear lever in raising utilization from 54%.
• What to watch next quarter: Whether binding bids arrive and at what valuation, the pace of new-hospital ramp-up in GCC, and any margin improvement in the clinics segment as the patient mix shifts toward premium networks.

GCC Restructuring & Value Unlock

• Process is independent: A committee of independent directors runs the sale, not management, because of conflict of interest; investment bankers interact directly with the committee.
• Timeline is tight: Shortlisted bidders have completed due diligence; binding bids are expected in Q1 FY24, with final buyer selection after negotiation of key terms and a close targeted before end-Q2.
• Structure is clean: India owns 100% of the GCC entity, so the entire sale proceeds, after deducting GCC debt, flow to the India-listed company.
• Tax efficiency: No capital gains tax arises on the sale because the holding company is in Mauritius and benefits from the Mauritius-India Tax Treaty.
• Valuation silence: Management declined to give any numbers on valuation, stating it cannot comment until binding bids are received and papers are signed.
• Promoter pledge is temporary: Promoters pledged 99% of their holding to raise roughly \$75 million for acquiring an additional 4% stake; a significant part of the loan is expected to be repaid as restructuring happens, and the pledge will fall away.

Dr. Azad Moopen: "This whole process is not run by us. It's not run by us because we have a conflict in interest. It's run by the independent directors. They have constituted a committee, and they are running this. We are completely out of that."

India Business: Growth & Margin Momentum

• Top-line acceleration: India revenue grew 25% for FY23 and 32% for Q4, driven by strong core healthcare demand that fully replaced COVID-era revenue.
• Profitability jump: India EBITDA rose 28% for FY23 and 62% for Q4; PAT grew 146% for the full year.
• Margin trajectory: India Hospitals & Clinics EBITDA margin improved 130 bps YoY to 18.7% in FY23, with Q4 reaching 15.8% versus 12.9% a year ago; management is targeting mid-teens by end-FY24.
• Three margin levers identified: Revenue assurance via ARPOB improvement (currently ₹36,000–₹37,000, held down by Kerala-heavy mix), cost optimization on materials and manpower per occupied bed, and occupancy leverage from the current 68%.
• Capacity is tight: Some India hospitals are at almost full capacity, prompting bed additions across multiple sites: 100 beds each at MIMS Kannur and Medcity Kochi, a 200-bed Kasargod project, Phase 1 of Trivandrum (350 beds), and Phase 2 of Whitefield (375 beds) nearing completion.
• Asset-light push: 390 beds were added under the O&M model during the year, reaching suburban areas with low CapEx; while margins may dilute slightly, ROCE can rise and the model carries an ESG element of taking services to grass-root levels.

Dr. Azad Moopen: "We see significant opportunities in India. That's a huge demand-supply gap as we know the market. And when we look at our peer group and all, they're doing extremely well. And we think that we have built up a lot of assets and we are also building up. And there is no reason why we shouldn't be at those levels as we go forward."

GCC Business: Investment Year, Recovery Path

• Revenue held up despite headwinds: GCC revenue grew 14% for FY23 and 16% for Q4, aided by expat inflows from Ukraine and Russia that reinstated some population lost during COVID.
• COVID revenue successfully replaced: COVID PCR revenue fell from ₹869 crores (roughly 11% of GCC business) in FY22 to just 1% in FY23, with core healthcare filling the gap.
• EBITDA flat for a reason: FY23 was an unprecedented investment year with three hospitals, 24 pharmacies and six clinics opened; roughly ₹100 crores invested in additional business, some paused during COVID, weighed on profitability.
• World Cup disruption: The unexpected Qatar World Cup caused schools to shut for six to eight weeks, sending expat families home and producing very reduced business during that period.
• New hospital ramp-up: Management aims for breakeven within 18 to 24 months of opening; Aster Narayanadri achieved breakeven in its first quarter, validating the timeline.
• Mature hospital margin upside: GCC mature hospitals operate at a 17% margin despite high ARPOB because cost points differ; utilization sits at 54%, and as that rises, margin improves.
• HR cost lever: HR cost is significantly higher than desired due to increasing competition in GCC; management is working on shared services and other measures, targeting a 3%–5% reduction.

Alisha Moopen: "It is unprecedented for our UAE and GCC business to have 3 hospitals, 24 pharmacies and 6 clinics in a year."

Clinics & Saudi Arabia Expansion

• Clinics turnaround underway: The clinics segment was most hit during COVID and sustained on COVID revenue for two years; FY23 was a turnaround year with 70%–80% of COVID business restored by normal operations.
• Patient mix shift is the margin story: Margins are squeezed by insurance on outpatient, with a large part in the lowest network; the strategy is to upgrade the brand toward premium customers and detach from lower-net-worth segments, with movement visible in the last six months.
• Sanad Hospital as Saudi anchor: Aster Sanad Hospital in Riyadh turned profitable with a 9% EBITDA margin this year after being loss-making for several years; it will serve as the hub for all other Saudi activities.
• Saudi pharmacy rollout: The first set of pharmacies in KSA is expected to go live by end-Q2 FY24; a new 59-bed extension to the Sanad facility opens in Q4.

Alisha Moopen: "Pricing will always be a challenge if we have a large part in the lowest network, which is why we're kind of upgrading the brand to be, we are building out more of the premium customers and sort of detaching some of lower net worth. So that's the best way for us to adjust the price and improve the quality of our revenue."

Digital & Omni-Channel Build-Out

• Significant investment: Approximately ₹100 crores was spent on digital initiatives in FY23, a significant portion directly affecting EBITDA and PAT.
• myAster App traction: The app maintained its position as the leading free medical app in UAE for several consecutive months; user base reached nearly 400,000, up from 220,000 in Q3; appointments booked through the app doubled quarter-on-quarter.
• E-pharmacy ramp: Monthly average run rate on e-pharmacy in Q4 surpassed Q3 by over 40%; home delivery revenue rose 18% versus the earlier part of the year.
• Partnership ecosystem: New tie-ups with Sukoon for health insurance plans, Dr. Reddy's Laboratories for medication access through Aster Pharmacy, and Talabat for prescription delivery in Dubai.
• Digital as growth driver: Management expects digital initiatives to be a key growth driver in coming years, with the omni-channel ecosystem strengthened by lab management restructuring and retail pharmacy expansion.

Guidance & Commitments

Key Metrics